Cost-effectiveness of Interventional therapies for management of Treatment-resistant hypertension: systematic review of pharmacoeconomic studies. Issue 4 (3rd September 2020)

• Record Type: Journal Article
• Authors: Mensa Sorato, Mende; Davari, Majid; Kebriaeezadeh, Abbas; Naderi, Nasim; Sarrafzadegan, Nizal; Shibru, Tamiru; Nikfar, Shekoufeh; Arero, Amanuel Godana
• Is Part Of: Journal of pharmaceutical health services research. Volume 11:Issue 4(2020:Dec.)
• Page Start: 307
• Page End: 319
• Publication Date: 2020-09-03
• Subjects: baroreceptor activation -- central arteriovenous anastomosis -- cost-effectiveness -- renal denervation -- systematic review -- treatment-resistant hypertension; Pharmacy -- Research -- Periodicals; Drugs -- Research -- Periodicals; Medical care -- Research -- Periodicals; Public health -- Research -- Periodicals; Pharmaceutical industry -- Periodicals; Health Services Research -- Periodicals; Economics, Pharmaceutical -- Periodicals; 615.1072
• DOI: 10.1111/jphs.12384
• Languages: English
• ISSNs: 1759-8885

Abstract

Abstract: Background: Treatment resistant hypertension (TRH) is defined as uncontrolled blood pressure (>140/90 mm Hg) after treatment with the intensified dose of three standard antihypertensive drugs. Management of TRH involves addition of fourth line drugs on standard care or interventional therapies (Renal denervation, Baroreceptor activation, Central venous anastomosis). However, evidence concerning cost-effectiveness of interventional therapies is inconclusive. Objective: This systematic review was conducted to extract the level of evidence on cost-effectiveness of interventional therapies for TRH. Method: We systematically searched articles written in English language since January 2000 to January 2020 from the following databases: PubMed/Medline, Ovid/Medline, Embase, Scopus, Web of Science, Google scholar and other relevant sources. Key findings: Twelve pharmacoeconomic studies were included in this systematic review. Renal denervation (RDN) is the most commonly studied intervention therapy for treatment of TRH. Participants included in the study vary from age 18-99 years. The incremental cost-effectiveness ratio (ICER) of RDN ranged from $1, 709.84 per QALY gained in Netherlands to 66, 380.3 per QALY gained in Australia. RDN was cost-effective in high-risk patients in UK, Australia, Canada, Netherlands, USA, Germany, Russia and Korea. The cost-effectiveness was influenced by the magnitude of effect of RDN on systolic blood pressure, the rate of RDN nonresponders, and the procedure costs of RDN and assumption of long-term time horizon. However, the ICER of RDN in Mexico was above MXN$ 139, 000 GDP/capita of the country. The ICER of implantable carotid body stimulator was $64, 400 per QALYs gained. The cost-effectiveness of baroreceptor activation didn't improve with age. Conclusion: Overall cost-effectiveness of interventional therapies for treatment of TRH was inconclusive based on the current available evidence. Therefore, strong clinical trials and pharmacoeconomic evaluations from different perspectives in various candidate populations are needed to generate adequate clinical and cost-effectiveness evidence for using interventional therapies in treatment of treatment resistant hypertension.